Counterfeit and diverted medicines are a key public health concern. Developing as well as developed countries are experiencing increases in patient safety risks due to these illicit drug forms. Public-private coordination between industry stakeholders and law enforcement can address the developments and trends in the counterfeit and diverted drug arena. In this piece, one such coordinated effort is described: the Pharmaceutical Security Institute, its membership drug manufacturer security directors, and law enforcement, to illustrate the power of such collaborations. With drug safety problems continuing globally, such partnerships are ever more important to promote safety of the drug supply.